Allergan reported second quarter fiscal year 2017 revenues of $4 billion on Aug. 8.
Here's what you should know:
1. The company reported a 9 percent growth in year-over-year revenue.
2. Allergan posted net generally accepted accounting principle operating income of $1.9 billion, a 1.6 percent year-over-year increase.
3. Allergan's Botox drove second quarter sales.
4. Concerning its gastrointestinal sector, Allergan's Linzess led the quartet of products with $167.8 million in revenues. Asacol/Delzicol revenues decreased 61.9 percent year-over-year to $45.6 million.
5. Concerning rest-of-year outlooks, Allergan expects net revenues between $15.85 billion and $16.05 billion.